✓ Every entry linked to its official government source

Clinical-trial readouts & FDA AdComm meetings — every entry source-anchored.

Upcoming clinical-trial readout windows (from ClinicalTrials.gov) and FDA Advisory Committee (AdComm) meetings (from the Federal Register), each linked to its official record and clearly labelled confirmed (a scheduled FDA meeting or completed event) or estimated (the sponsor's projected trial-completion date). Public scheduling data, not investment advice.

See the calendar → Get the feed / API

What "source-anchored" means here

Every row is read directly from an official government field and links straight back to it, stamped with the date we last checked. We do not dress up an estimate as a fixed date: trial-readout rows carry the sponsor's estimated primary-completion date (which can slip), while FDA AdComm meetings carry a confirmed, scheduled date from the Federal Register Notice of Meeting. Each row says which it is, and you can audit it in one click.

603

upcoming source-anchored catalysts

600

trial primary-completion / readout dates EST

75

FDA AdComm meetings CONFIRMED

264

mapped to a public ticker

Most upcoming entries are clinical-trial readout windows carrying the sponsor's estimated primary-completion date (it can slip). FDA AdComm meetings carry a confirmed scheduled date. Every row is labelled and linked to its official source.

Soonest upcoming catalysts

Source-checked 2026-09-20 · refreshed daily · full calendar →

Date	Event	Company	Drug	Official source & verification
2026-09-21 in 1d ESTIMATED	READOUT CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) Phase 3 · Recurrent Pericarditis	CRDL Cardiol Therapeutics Inc.	CardiolRx	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-22 in 2d ESTIMATED	READOUT A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and i Phase 1/2 · Solid Tumor, Melanoma	ImmVira Pharma Co. Ltd	T3011, T3011 + pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-22 in 2d ESTIMATED	READOUT A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Mono Phase 2 · Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent	ONC BeOne Medicines Ltd.	Sonrotoclax, Zanubrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-22 in 2d ESTIMATED	READOUT Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 an Phase 1/2 · Norovirus Acute Gastroenteritis	ModernaTX, Inc.	mRNA-1403, mRNA-1405	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-23 in 3d ESTIMATED	READOUT Study to Test the Safety and Tolerability of PF-07220060 in Participants With Ad Phase 2 · Liposarcoma, Prostate Cancer	PFE PFIZER INC	PF-07220060, Letrozole, Fulvestrant, Mid	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-23 in 3d CONFIRMED	ADCOM Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee	Molecular and Clinical Genetics Pa	AdComm review	Federal Register (FDA notice) ↗ ✓ Source-checked 2026-09-20 Scheduled FDA meeting date
2026-09-24 in 4d ESTIMATED	READOUT An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 Phase 1/2 · Systemic Lupus Erythematosus, Lupus Nephritis	NVS NOVARTIS AG	YTB323	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-27 in 7d ESTIMATED	READOUT A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whethe Phase 3 · Lupus Erythematosus, Systemic	BIIB BIOGEN INC.	Litifilimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-28 in 8d ESTIMATED	READOUT A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Phase 2 · Cutaneous Squamous Cell Carcinoma	INCY INCYTE CORP	INCB099280	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-28 in 8d ESTIMATED	READOUT A Study of AT-02 in Subjects With Systemic Amyloidosis. Phase 2 · Amyloidosis; Systemic	Attralus, Inc.	AT02	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-28 in 8d ESTIMATED	READOUT A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Di Phase 2/3 · Stargardt Disease	OCGN Ocugen, Inc.	OCU410ST	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-28 in 8d ESTIMATED	READOUT An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcu Phase 3 · Hidradenitis Suppurativa	MLTX MoonLake Immunotherapeutics	Sonelokimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-29 in 9d ESTIMATED	READOUT Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Rela Phase 3 · Eosinophilic Granulomatosis With Polyangiitis	GlaxoSmithKline	Depemokimab, Mepolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-29 in 9d ESTIMATED	READOUT Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Pa Phase 2 · Asthma	SNY Sanofi	Amlitelimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled Phase 2/3 · Refractory Schizophrenia	SyneuRx International (Taiwan) Cor	NaBen®	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib i Phase 1/2 · Indolent B-Cell Non-Hodgkin Lymphoma	BioInvent International AB	BI-1206, Rituximab, Acalabrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, RO Phase 1/2 · Locally Advanced Solid Tumors, Metastatic Solid Tumors	TPB Turning Point Brands, Inc.	Oral repotrectinib (TPX-0005)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT Linerixibat Long-term Safety, and Tolerability Study Phase 3 · Cholestasis	GlaxoSmithKline	Linerixibat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Part Phase 3 · Carcinoma, Non-Small-Cell Lung	Hoffmann-La Roche	Entrectinib, Crizotinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whethe Phase 3 · Lupus Erythematosus, Systemic	BIIB BIOGEN INC.	Litifilimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Particip Phase 3 · Stereotypical Prolonged Seizures	UCB Biopharma SRL	Staccato alprazolam	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizum Phase 3 · Gastric Neoplasms, Gastroesophageal Adenocarcinoma	JAZZ Jazz Pharmaceuticals plc	Zanidatamab, Tislelizumab, Trastuzumab,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab Phase 3 · Non-Small Cell Lung Cancer	AZN ASTRAZENECA PLC	Durvalumab, Oleclumab, Monalizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Phase 1/2 · KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung	NVS NOVARTIS AG	JDQ443, trametinib, Ribociclib, cetuxima	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Pati Phase 1/2 · EGFR Mutant Advanced Non-small Cell Lung Cancer	J Ints Bio	JIN-A02	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change